Europe Proteomics Market

The report "Europe Proteomics Market by Instrumentation [Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray], Reagent (Immunoassay), Service (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery)- Forecast to 2030" is projected to reach USD 18.77 billion by 2030 from USD 10.55 billion in 2025, at a CAGR of 12.2%  during the forecast period.

Browse 983 market data Tables and 57 Figures spread through 781 Pages and in-depth TOC on "Europe Proteomics Market, By Instrumentation [Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray], Reagent (Immunoassay), Service (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery)- Forecast to 2030 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-proteomics-market-22726998.html

The Europe proteomics market is experiencing growth, driven by increasing aging population, rising chronic diseases, and continuous improvements and technological advancements.

The immunoassay reagent segment accounted for the largest share of the Europe proteomics market, by reagent, in 2024.

By reagent, the proteomics market is segmented into  immunoassay reagents, spectroscopy reagents, chromatography reagents, protein microarray reagents, X-ray crystallography reagents, electrophoresis reagents, protein fractionation reagents, other reagents. In 2024, immunoassay reagents occupied the highest market share, followed by their strong sensitivity, automation compatibility for high throughput, and applicability in various ELISAs, multiplex bead technology, and proximity extension techniques assays. These reagents facilitate the quantification of low-abundance biomarkers, support extended validation studies, and are easily integrated into various healthcare applications, such as cancer diagnostics, autoimmune analyses, and more. This makes them essential for both biopharma companies and research labs for scalable protein analysis.

In 2024, the cancer subsegment is expected to be the fastest-growing in the Europe proteomics market, by clinical diagnostic.

By clinical diagnostic, the market is divided into cancer, infectious diseases, diabetes, neurological disorders, autoimmune diseases, cardiovascular diseases, and other clinical diagnostic applications. In 2024, Cancer was the fastest-growing segment due to surging demand for liquid biopsy-based protein biomarkers to enable early cancer detection, minimal residual disease monitoring, and therapy response prediction. High-throughput plasma proteomics panels, powered by advanced mass spectrometry and proximity extension assays, deliver unmatched sensitivity for low-abundance tumor-specific proteoforms across cancers like lung, breast, and colorectal. EU-funded precision oncology initiatives and national screening programs accelerate adoption, positioning proteomics as the cornerstone for personalized immunotherapy selection and companion diagnostics in Europe's expanding cancer care infrastructure.

Germany accounted for the largest regional share in the Europe proteomics market in 2024.

The market for European proteomics is segmented into Germany, the UK, France, Switzerland, Italy, Spain, and the rest of Europe. In 2024, Germany commands the largest share in the Europe proteomics market due to its powerhouse biopharma ecosystem, including giants like Merck KGaA and BioNTech, world-class institutes such as Max Planck and EMBL, and massive R&D funding from national programs. Dense biotech clusters in Munich and Heidelberg, along with rapid adoption of advanced MS and single-cell proteomics technologies, cement its regional dominance.

Key players in the European proteomics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Qiagen (Netherlands), Agilent Technologies (US), Bruker Corporation (US), Bio-Rad Laboratories (US), Eurofins (Luxembourg), and Protagene (Germany).

Don’t miss out on business opportunities in European proteomics market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com